Hemispherx BioPharma, Inc  

(Public, NYSEMKT:HEB)   Watch this stock  
Find more results for heb
0.500
+0.001 (0.22%)
Feb 24 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.48 - 0.50
52 week 0.39 - 2.64
Open 0.50
Vol / Avg. 121,037.00/355,201.00
Mkt cap 13.30M
P/E     -
Div/yield     -
EPS -0.45
Shares 26.12M
Beta -0.16
Inst. own 14%
Mar 27, 2017
Q4 2016 Hemispherx Biopharma Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -13009.09% -11451.13%
Operating margin -13659.09% -12755.64%
EBITD margin - -11624.06%
Return on average assets -52.79% -58.30%
Return on average equity -67.29% -67.13%
Employees 30 -
CDP Score - -

Address

One Penn Center 1617 Jfk Blvd, Suite #500
PHILADELPHIA, PA 19103
United States - Map
+1-215-9880080 (Phone)
+1-215-9881739 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Officers and directors

William M. Mitchell M.D., Ph.D. Chairman of the Board
Age: 80
Bio & Compensation  - Reuters
Thomas K. Equels Esq. President, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Adam Pascale CPA Chief Financial Officer
Bio & Compensation  - Reuters
Wayne Steven Springate Senior Vice President - Operations
Age: 44
Bio & Compensation  - Reuters
David R. Strayer M.D. Chief Scientific Officer
Age: 69
Bio & Compensation  - Reuters
Peter W. Rodino III., Esq. Executive Director - Governmental Relations, General Counsel
Age: 64
Bio & Compensation  - Reuters